MedPath

Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty

Completed
Conditions
Status Post Total Hip and Knee Arthroplasty
Registration Number
NCT02648295
Lead Sponsor
West Virginia University
Brief Summary

Blood management is an important part of successful total joint replacement. Loss of blood and transfusion can lead to poor outcomes for patients. The use of tranexamic acid (TXA) has become a standard component to many blood management programs. It is used to treat or prevent excessive blood loss during surgery and in various medical conditions such as excessive bleeding or hemorrhage. A normal body process prevents blood clots that occur naturally from growing and causing problems. When this process becomes overactive it can result in excessive bleeding, leading to increased blood transfusions. The proposed study seeks to evaluate the relationship between TXA and thromboelastogram (TEG) results.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Primary total hip and knee arthroplasty patients presenting to WVU Center for Joint Replacement
  • 40-90 years old
Exclusion Criteria
  • Known coagulopathy
  • History of venothrombotic event
  • Unstable angina
  • Recent Myocardial infarction (MI)
  • History of bleeding events
  • History of chronic anemia
  • Preoperative anemia
  • Current use of blood thinners including aspirin

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All time measurements which indicate various aspects of clotting cascade3 months

Data derived from the TEG which includes R, MA, LY30 (R = clotting factors, MA clot strength and platelet function and LY30 is fibrinolysis).

Secondary Outcome Measures
NameTimeMethod
Blood loss and transfusions3 months

Estimated and Calculated blood loss and transfusion requirements

© Copyright 2025. All Rights Reserved by MedPath